Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 5/20 | 0.42 |
| ▸ | SAT1 | P21673 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.32 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.32 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 3/20 | 0.30 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21003492 | 1.00 | CYP2C19 (0.56) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL8343514 | 1.00 | CYP2C19 (0.56) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL1788030 | 0.97 | — | — | |
| Bromide SCHEMBL7116645 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL7115854 | 0.93 | — | — | |
| Iodide SCHEMBL7112955 | 0.93 | — | — | |
| SCHEMBL16948506 | 0.86 | CARM1 (0.39) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL30612397 | 0.86 | CYP2C19 (0.71) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL2893263 | 0.86 | CYP2C19 (0.71) | CYP2C19MEN1GLAKMT2ACYP1A2 | |
| SCHEMBL6131298 | 0.86 | CARM1 (0.39) | CYP2C19MEN1GLAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3188799-B1 | METHODS FOR TREATING AGING AND SKIN DISORDERS USING NUCLEIC ACIDS TARGETING TYR OR MMP1 | PHIO PHARM CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11118178-B2 | Reduced size self-delivering RNAI compounds | PHIO PHARMACEUTICALS CORP. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2019032619-A9 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | PHIO PHARMACEUTICALS CORP. (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-2550001-B1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARM CORP (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2019032619-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | PHIO PHARMACEUTICALS CORP. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20170067056-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | RXI PHARMACEUTICALS CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170051288-A1 | METHODS FOR TREATING CANCER USING NUCLEIC ACIDS TARGETING MDM2 OR MYCN | RXI PHARMACEUTICALS CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2017007813-A1 | NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) | RXI PHARMACEUTICALS CORPORATION (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20160304875-A1 | METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES | RXI PHARMACEUTICALS CORPORATION (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160130578-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2016-05-12 | — | — | US | disclosed |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2016-04-28 | — | — | US | disclosed |
| WO-2015168108-A2 | METHODS FOR TREATING CANCER USING NUCLEIC TARGETING MDM2 OR MYCN | RXI PHARMACEUTICALS CORPORATION (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015168605-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | RXI PHARMACEUTICALS CORPORATION (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9095504-B2 | RNA interference in ocular indications | RXI PHARMACEUTICALS CORPORATION | 2015-08-04 | — | — | US | disclosed |
| US-9080171-B2 | Reduced size self-delivering RNAi compounds | RXi Parmaceuticals Corporation (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140113950-A1 | INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| US-20130131141-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| EP-0058505-A1 | Preparation of esters containing an alpha-cyano group in the alcohol portion of the esters | FMC Corporation (US) | 1982-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11118178-B2 | Reduced size self-delivering RNAI compounds | SNRPE, SARNP, LDLR | CYP2C19 4883/4885MEN1 4272/4885GLA 3959/4885 |
| US-20160304875-A1 | METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES | FN1, RXFP1, MMP1 | CYP2C19 4743/4885MEN1 4351/4885GLA 882/4885 |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | CYP2C19 4442/4885MEN1 4837/4885GLA 3411/4885 |
| US-20170051290-A1 | METHODS FOR TREATMENT OF DISORDERS IN THE FRONT OF THE EYE UTILIZING NUCLEIC ACID MOLECULES | POLRMT, NSUN3, ELAVL1 | CYP2C19 4881/4885MEN1 1278/4885GLA 1643/4885 |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | CYP2C19 4442/4885MEN1 4837/4885GLA 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.